FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783284150> ?p ?o ?g. }

• W2783284150 endingPage "5410" @default.
• W2783284150 startingPage "5410" @default.
• W2783284150 abstract "Abstract Introduction Multiple myeloma is known to have progressive mutations that lead to a dominant aberrant plasma cell clone and a number of subclones. Mutations can lead to more aggressive forms of myeloma, but rarely does it transform into an immature variant such as anaplastic myeloma. This particular variant has a predisposition for extramedullary sites and is related to IgA plasma cell variants. Unlike standard myeloma that responds better to novel agents such as proteasome inhibitors and immunomodulators, this poorly differentiated cell is highly resistant to therapy and has very poor outcomes. In the following case report, we present a patient with IgA kappa anaplastic myeloma that evolved from multiple myeloma. We will demonstrate how a combination of novel agents in conjunction with conventional chemotherapy was a successful therapy for both plasma cell variants. Case Report A 60 year-old man had a three month history of confusion, headaches, and leg weakness. He did not seek medical attention until he lost vision on his right eye. On exam, he had right ptosis with a dilated pupil fixed downward and laterally. MRI of the orbit showed a right orbital apex mass surrounding the optic nerve and diffuse leptomeningeal enhancement. A PET/CT, to better characterize the extent of disease showed right laryngeal, lung, and femoral hypermetabolic lesions in addition to the orbital mass. A biopsy of the laryngeal mass showed an IgG kappa anaplastic myeloma with Ki-67 of 70% and FISH positive for +12 and +14. Serology demonstrated an IgA M-spike of 1.56 with an abnormal serum free light chain ratio of 118.31. He underwent a bone marrow biopsy that showed 30% kappa-restricted plasma cells with 13q- and +11 by FISH and a lumbar puncture that demonstrated CNS involvement by CD38+ clonal plasma cells. He was classified as systemic stage I IgA kappa myeloma by R-ISS with localized anaplastic myeloma showing similar light chain restriction by immunohistochemistry. The patient received HD methotrexate 3 g IV with evidence of leptomeningeal response but evidence of sytemic progression on eye mass within a week despite of stable myeloma serology. He received 4 Gy as a single dose to the eye mas that shrunk the tumor. HyperCVAD with IT cytarabine alternating with MTX was started with a significant improvement in plasmacytomas by PET scan after 2 cycles of therapy. Flow cytometry from CNS became negative at that time but paraprotein remained unchanged. A bone marrow biopsy performed after the 4th cycle of chemotherapy showed 30% clonal plasma cells with stable M-spike at 1.45 and serum free light chain ratio of 79. Seeing that the CNS fluid was now negative and the orbital and leptomeningeal lesions had improved, therapy was changed to carfilzomib, pomalidomide, and dexamethasone but continued on IT chemotherapy alternating cytarabine and MTX. His M-spike resolved after 3 cycles of treatment. His immunofixation continued to detect IgA kappa clone and serum free light chain ratio dropped to 19.08. Follow up The patient continues tolerating treatment with no evidence of systemic or CNS relapse disease. He remains on carfilzomib, pomalidomide, and dexamethasone as maintenance for systemic therapy combined with monthly IT chemotherapy. He developed one episode of confusion thought to be from white matter changes from IT chemotherapy but those symptoms have resolved. Discussion This unique scenario of a patient having both myeloma and anaplastic myeloma poses a challenge in management. While novel agents may be good to control the myeloma, more primitive forms of myeloma cells do not have the epitopes these agents bind to in order to cause cell destruction. Since anaplastic myeloma is more aggressive, targeting it with conventional chemotherapy that penetrated the CNS barrier seemed like a good initial treatment until CNS disease control was achieved, with focus on the more indolent myeloma afterwards with novel agents. Out of those, we included one known to have CNS penetration (pomalidomide). This approach was effective in this case and could be applied in future cases as clinical trials on such rare disease wouldn't be feasible. The similarities between the two plasma cell neoplasms shows the significant difference myeloma subclones can have. This proves the concept that myeloma does not behave as a single tumor, but more like clusters of different myeloma strains that can branch off the dominant clone and lead to relapse or refractory disease. Disclosures Rodriguez: Celgene: Other: advisory board, Speakers Bureau; Takeda: Speakers Bureau." @default.
• W2783284150 created "2018-01-26" @default.
• W2783284150 creator A5023144181 @default.
• W2783284150 creator A5033256635 @default.
• W2783284150 creator A5040152817 @default.
• W2783284150 date "2017-12-07" @default.
• W2783284150 modified "2023-09-29" @default.
• W2783284150 title "Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual" @default.
• W2783284150 doi "https://doi.org/10.1182/blood.v130.suppl_1.5410.5410" @default.
• W2783284150 hasPublicationYear "2017" @default.
• W2783284150 type Work @default.
• W2783284150 sameAs 2783284150 @default.
• W2783284150 citedByCount "0" @default.
• W2783284150 crossrefType "journal-article" @default.
• W2783284150 hasAuthorship W2783284150A5023144181 @default.
• W2783284150 hasAuthorship W2783284150A5033256635 @default.
• W2783284150 hasAuthorship W2783284150A5040152817 @default.
• W2783284150 hasConcept C126322002 @default.
• W2783284150 hasConcept C142724271 @default.
• W2783284150 hasConcept C2776364478 @default.
• W2783284150 hasConcept C2776396001 @default.
• W2783284150 hasConcept C2778964538 @default.
• W2783284150 hasConcept C2908937092 @default.
• W2783284150 hasConcept C2909638373 @default.
• W2783284150 hasConcept C71924100 @default.
• W2783284150 hasConceptScore W2783284150C126322002 @default.
• W2783284150 hasConceptScore W2783284150C142724271 @default.
• W2783284150 hasConceptScore W2783284150C2776364478 @default.
• W2783284150 hasConceptScore W2783284150C2776396001 @default.
• W2783284150 hasConceptScore W2783284150C2778964538 @default.
• W2783284150 hasConceptScore W2783284150C2908937092 @default.
• W2783284150 hasConceptScore W2783284150C2909638373 @default.
• W2783284150 hasConceptScore W2783284150C71924100 @default.
• W2783284150 hasLocation W27832841501 @default.
• W2783284150 hasOpenAccess W2783284150 @default.
• W2783284150 hasPrimaryLocation W27832841501 @default.
• W2783284150 hasRelatedWork W1578872576 @default.
• W2783284150 hasRelatedWork W187905365 @default.
• W2783284150 hasRelatedWork W2014420907 @default.
• W2783284150 hasRelatedWork W2023211575 @default.
• W2783284150 hasRelatedWork W2081643520 @default.
• W2783284150 hasRelatedWork W209935236 @default.
• W2783284150 hasRelatedWork W2151226252 @default.
• W2783284150 hasRelatedWork W2162224041 @default.
• W2783284150 hasRelatedWork W2326545309 @default.
• W2783284150 hasRelatedWork W23283875 @default.
• W2783284150 hasRelatedWork W2409234368 @default.
• W2783284150 hasRelatedWork W2412069412 @default.
• W2783284150 hasRelatedWork W2556481893 @default.
• W2783284150 hasRelatedWork W2966476161 @default.
• W2783284150 hasRelatedWork W3030146407 @default.
• W2783284150 hasRelatedWork W3042504017 @default.
• W2783284150 hasRelatedWork W3211805957 @default.
• W2783284150 hasRelatedWork W8770943 @default.
• W2783284150 hasRelatedWork W2187942246 @default.
• W2783284150 hasRelatedWork W62118138 @default.
• W2783284150 hasVolume "130" @default.
• W2783284150 isParatext "false" @default.
• W2783284150 isRetracted "false" @default.
• W2783284150 magId "2783284150" @default.
• W2783284150 workType "article" @default.